Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Natera

Biotech & Life Sciences · Austin, United States · Founded 2004 · IPO 2015 Decacorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$27B
Market cap · May/2026
Revenue
$2.30B
Latest reported FY

Harnessing the power of DNA to improve the management of reproductive health, cancer, and organ transplants

Investors

13 investors on Natera's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Claremont Creek Ventures
Sequoia
Series B+ 11 investors entered at this stage

Global footprint

Where Natera has talent and traffic

AI talent share
1.4% of workforce is AI talent
(81 of 5,669 staff)
Core AI250.44%
Other AI560.99%
Non-AI workforce5,58898.57%
Workforce by country
40 countries with
team presence
🇺🇸 United States95.4%
🇷🇸 Serbia1.7%
🇷🇺 Russia0.6%
🇨🇦 Canada0.3%
🇬🇹 Guatemala0.2%
Top 5 of 40 shown
Web traffic by country
1.1M monthly visits
across markets
🇺🇸 United States92.4%
🇩🇪 Germany0.9%
🇨🇦 Canada0.4%
🏳️ Korea0.3%
🏳️ Republic of0.3%
Top 5 markets shown

Patent intelligence

$71M patent portfolio · 59 active families

Estimated portfolio value
$71M
0.26% of market cap · 1.5× smaller than top peer Resilience ($108M)
59 active patent families
Where Natera innovates CellBioinformaticsMedicineNucleic acidComputational biology

Where Natera concentrates vs peers

Each axis is a top-10 topic across Natera and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Natera's 2 investments and acquisitions.

Every disclosed deal where Natera appeared as a backer or acquirer, 2022–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Natera's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Natera deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Natera's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Sentiment on X

        What X is saying about Natera

        An AI-synthesized read of the highest-engagement posts about Natera on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Natera on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.